Patents Examined by Laura B Goddard
  • Patent number: 11067578
    Abstract: The present inventors have demonstrated that circulating auto-antibodies to cancer antigens hold promise as specific and sensitive biomarkers for the early detection of cancer. The present invention thus relates to methods of detecting cancer in a sample, comprising utilising a glycopeptide bait derived from human mucins with different cancer-associated O-glycans. Detected antibodies were demonstrated as glycopeptide specific, and it could be discriminated between e.g. colorectal cancer patients and healthy individuals. The inventors have also developed monoclonal antibodies based on the identified glycopeptides epitope baits, and demonstrated differential expression of the relevant target antigens. The invention thus, in a lock and key-based manner includes both glycopeptides and antibody tools for early detection of cancer, as well as methods of using the same for in situ visualisation and treatment of specific cancer types.
    Type: Grant
    Filed: October 16, 2018
    Date of Patent: July 20, 2021
    Assignee: GO Therapeutics, Inc.
    Inventors: Hans H. Wandall, Johannes Wirenfeldt Vad Pedersen, Eric Paul Bennett, Henrik Clausen, Ulla Mandel
  • Patent number: 11065330
    Abstract: The invention relates to a pharmaceutical composition for modulation of T cell and B cell responses by antigen- or allergen-specific immunotherapy in combination with peripheral tolerance-inducing phagocytosis, made of one or more preparations and comprising one or more matrices suitable for locally restricted sustained release of a physiologically effective dose of at least one antigen or allergen, liposomes tailored for effective phagocytosis, one or more immune modulators of phagocytosis, and one or more immune modulators suitable for enhancing the suppressive function of regulatory T cells at the site of antigen or allergen presentation.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: July 20, 2021
    Assignee: PLS-Design GmbH
    Inventors: Reinhard Bredehorst, Thomas Grunwald, Carsten Schmidt-Weber
  • Patent number: 11058768
    Abstract: A stable pharmaceutical formulation comprising a protein of interest, sorbitol and polyethylene glycol (PEG). The sorbitol and protein is present in a molar ratio of 550 to 700 mole of sorbitol:1 mole of protein and the PEG to protein is present in the molar ratio of 2-50:1. The formulation optionally comprising buffer. The formulation in lyophilised form is stable for at least 4 years at 2-8° C. Also provided is a process for preparing the composition and a pharmaceutical kit comprising the same.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: July 13, 2021
    Inventors: Kala Chandramouli, Rohan Pai
  • Patent number: 11046777
    Abstract: The present invention comprises human monoclonal antibodies that bind to GITR (also known as glucocorticoid-induced tumor necrosis factor receptor). Binding of the invented antibody to GITR inhibits binding of its ligand, GITR-L, and can be used to treat cancer.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: June 29, 2021
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Wayne A. Marasco, Quan Karen Zhu
  • Patent number: 11001634
    Abstract: The present disclosure relates to a neuregulin non competitive allosteric anti-human-HER3 antibody having a human constant region; and less than 65% of the glycan structures carried by the glycosylation site of the antibody comprises a fucose molecule. The antibody is characterized by its variable sequences.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: May 11, 2021
    Inventors: Thierry Chardès, Olivier Dubreuil, André Pelegrin, Christel Larbouret, Jean-François Prost, Jean-Marc Barret, Stéphane Degove
  • Patent number: 11001638
    Abstract: The invention relates to antibodies specific for 4-1BB and OX40, as well as to methods for using such antibodies and therapeutic uses thereof.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: May 11, 2021
    Assignee: Cancer Research Technology Limited
    Inventors: Aymen Al-Shamkhani, Hak Tak Claude Chan, Mark Steven Cragg, Ruth Rosemary French, Martin John Glennie, Jane Elizabeth Willoughby
  • Patent number: 10996215
    Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: May 4, 2021
    Inventors: Matthew William Burnell Trotter, Patrick Hagner, Courtney G. Havens, Rajesh Chopra, Anita Gandhi, Anke Klippel, Maria Yinglin Wang, Mike Breider, Suzana Sturlini Couto, Yan Ren, Paul Hollenbach, Kyle Macbeth
  • Patent number: 10973896
    Abstract: The present invention relates to a method of treating or preventing melanoma using vaccination or immunisation, wherein said vaccination or immunisation involves the use of a photosensitizing agent, a melanoma antigen (i.e. an antigenic molecule), for example a vaccine component, and irradiation with light of a wavelength effective to activate the photosensitizing agent. The invention also relates to said photosensitizing agent and melanoma antigen for use in such a method, and to cells produced by the method.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 13, 2021
    Assignee: PCI Biotech AS
    Inventors: Anders Høgset, Pål Johansen
  • Patent number: 10962543
    Abstract: Provided herein are methods of treating a nonhematopoietic malignant tumor in a patient and methods of prognosing a nonhematopoietic malignant tumor in a patient, comprising administering to the patient a therapeutically effective amount of an agent that preferentially kills or inhibits proliferation or activity of leukocytes relative to nonhematopoietic cells.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: March 30, 2021
    Assignee: Memorial Sloan Kettering Cancer Center
    Inventors: Larry Norton, Ross Levine, Maria Kleppe, Elizabeth Comen
  • Patent number: 10961318
    Abstract: Anti-SIRP? antibodies, including multi-specific anti-SIRP? antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRP? and can block the interaction of CD47 on one cell with SIRP? on a phagocytic cell.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 30, 2021
    Assignee: Forty Seven, Inc.
    Inventors: Jie Liu, Jens-Peter Volkmer
  • Patent number: 10947319
    Abstract: Provided herein are biparatopic antigen-binding constructs that specifically bind HER2. The biparatopic antigen-binding constructs comprise one antigen-binding moiety that binds to ECD2 of HER2, a second antigen-binding moiety that binds to ECD4 of HER2, and an Fc. At least one of the antigen-binding moieties is an scFv. The biparatopic antigen-binding constructs can be used in the treatment of cancer.
    Type: Grant
    Filed: November 27, 2014
    Date of Patent: March 16, 2021
    Assignee: Zymeworks Inc.
    Inventors: Nina E. Weisser, Gordon Yiu Kon Ng, Grant Raymond Wickman, Surjit Bhimarao Dixit, Eric Escobar-Cabrera, Mario Sanches
  • Patent number: 10940112
    Abstract: This disclosure relates to a targeted PEGylated liposomal gemcitabine (PLG) composition comprising a PEGylated liposome encapsulating one or more agents comprising gemcitabine and a targeting moiety; pharmaceutical composition and methods comprising PLG or producing PLG; and manufacturing equipment for performing the methods.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: March 9, 2021
    Assignee: L.E.A.F. Holdings Group LLC
    Inventors: Clet Niyikiza, Victor Moyo, Zhenghong Xu, Kaniz Khalifa
  • Patent number: 10927170
    Abstract: Use of anti-Claudin 1 monoclonal antibodies and pharmaceutical compositions thereof, for the prevention and/or treatment of hepatocellular carcinoma in patients suffering from liver disease, in particular liver disease that is not associated with HCV infection or in patients who have been cured from HCV infection. Methods of preventing and/or treating hepatocellular carcinoma by administration of such a monoclonal antibody, or a pharmaceutical composition thereof, are also described. Experimental results with the hepatocarcinoma cell line HuH-7.5.1 are given.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: February 23, 2021
    Assignees: Universite de Strasbourg, Institut Hospitalier Universitaire de Strasbourg, Institut National de la Sante et de la Recherche Medicale
    Inventors: Thomas Baumert, Eric Robinet, Mirjam Zeisel
  • Patent number: 10919947
    Abstract: The present invention relates to a pharmaceutical composition containing, as an active ingredient, a fusion protein in which a tissue-penetrating peptide and an anti-vascular endothelial cell growth factor (anti-VEGF) agent are fused, for treating cancer or angiogenesis-related diseases. More specifically, the present invention relates to a use of the fusion protein for treating cancer or angiogenesis-related diseases, wherein the fusion protein improves the tissue penetrability of an anti-vascular endothelial cell growth factor agent and exerts a cancer targeting effect, thereby producing an excellent angiogenesis inhibiting effect and exhibiting a therapeutic effect on cancer showing resistance or unresponsiveness to the anti-VEGF agent.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 16, 2021
    Inventors: Hyuk-Sang Kwon, Jong-Hee Ko, Young-Min Lee, Hyei-Yoon Jung, Seok-Woo Yang, Jae-Hoon Kang, Yong-Sung Kim
  • Patent number: 10906963
    Abstract: The present invention relates to variants of the anti-tenascin antibody F16 which are modified to abolish N-glycosylation at positions 88 to 90 in the VL domain. This results in dramatically improved properties, such as improved binding affinity and tumour biodistribution in vivo. Variant F16 antibody molecules and methods for their production and use are provided.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: February 2, 2021
    Assignee: Philogen S.P.A
    Inventors: Rémy Gébleux, Sarah Wulhfard
  • Patent number: 10889636
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: January 12, 2021
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Patent number: 10874724
    Abstract: In some embodiments the present disclosure pertains to a method of activating an anti-tumor immune response for the treatment of a cancer. In some embodiments, such a method comprises detecting CD26 expression in a subject in need thereof. In some embodiments, the method comprises administering to the subject a therapeutically effective amount of a composition comprising adenosine deaminase. In some embodiments, the adenosine deaminase stimulates T cell proliferation and activates maturation of macrophages or dendritic cells. In some embodiments, the present disclosure pertains to a method for targeted reduction of adenosine or deoxyadenosine in a tumor microenvironment of a solid tumor.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: December 29, 2020
    Inventors: Navin Varadarajan, Irfan Naseem Bandey
  • Patent number: 10870694
    Abstract: The present invention comprises methods of using a humanized monoclonal antibody that binds to the human immunoglobulin heavy chain variable region germline gene VH1-69 to treat B-cell disorders.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: December 22, 2020
    Assignee: Dana Farber Cancer Institute, Inc.
    Inventor: Wayne A. Marasco
  • Patent number: 10870701
    Abstract: The present invention provides multispecific Fab fusion proteins (MSFP) that specifically bind to CD3 and EpCAM. The present invention further provides uses of the MSFPs for the preparation of pharmaceutical compositions, methods of treating cancer, and kits comprising the MSFPs. Also provided are anti-EpCAM antibodies or antigen-binding fragments thereof.
    Type: Grant
    Filed: March 15, 2017
    Date of Patent: December 22, 2020
    Assignee: Generon (Shanghai) Corporation Ltd.
    Inventors: Yumin Cui, Zhihua Huang, Hanyang Chen, Xinfeng Zhang, Bo Qi, Xiaoqiang Yan
  • Patent number: 10865245
    Abstract: The invention is directed to novel antibody binding compounds specific for the human B7H3 and uses of such compounds for diagnostic and therapeutic purposes.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: December 15, 2020
    Assignee: Full Spectrum Genetics, Inc.
    Inventors: Robert DuBridge, Veronica Juan